Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
about
Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adultsCurrent applications of graphene oxide in nanomedicineA Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in DogsPomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicinesViral profiling identifies multiple subtypes of Kaposi's sarcoma.Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural MalawiClinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South AfricaA mixed methods approach to adapting and evaluating the functional assessment of HIV infection (FAHI), Swahili version, for use with low literacy populationsmTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Hepatic Kaposi sarcoma: A case report and review of the literature.Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.Pharmacological management of Kaposi's sarcoma.Systemic management strategies for metastatic soft tissue sarcoma.Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.Advances in the systemic treatment of cutaneous sarcomas.Pegylated liposomal doxorubicin: a guide to its use in various malignancies.Diagnosis and Treatment of Kaposi Sarcoma.Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).Infection of KSHV and Interaction with HIV: The Bad Romance.
P2860
Q24193874-38F70F69-D537-4137-91DA-3F83EF158AFDQ26783225-6D4DF8D7-30DD-48C9-B766-F736DD4BCAEEQ26801149-74E2D808-ADC8-47F5-AC06-A4BC2F4C0523Q33816582-07625BF6-A155-430B-A1FE-1343AE630936Q34045119-19899A15-8E3E-4C73-AED2-663A30068AA3Q34237734-8E1D99F5-2675-4A4C-991D-93CB5F6E1B21Q35294664-7826187A-EEDA-4E6F-854D-3CDE06F9E551Q35668862-88F7A95E-0089-41EE-B34E-2616DE72D76BQ35795414-E3EDAB77-0054-4C4B-AB09-7A5004EC7EDDQ35989731-7B9BB1F9-B831-49D5-9A48-FE433499527CQ36336208-BD493FE0-2A49-4DBE-B6A2-41410B136308Q36745445-17A3836F-226C-4755-AC20-B869021E8ED3Q36818306-31DAF136-00B7-4EA3-9E88-F2AF5A8C6091Q37467770-90791518-472B-4080-BA6A-1EE1557732C3Q37628536-273A1AD3-90EC-4DD6-A9AF-4986D264226AQ37689857-70FF8A99-74A0-4FCF-A3E3-460EDCB7F1D5Q37868566-307E6DC3-B903-43F3-98CA-1D7C2272FD26Q37950516-F8E27314-C508-4CEE-BF05-92C46D8D3635Q37964713-DBBBBDC4-ABC7-459C-B113-4D79115CD1EEQ38000872-B58EC6FA-5598-4A0D-A73E-993EFFDD7178Q38135689-3825323C-B7FE-41B1-A5AB-5D0EF86881B7Q39190555-9C87FB44-801B-4BA8-9462-6613AA31ECE4Q43923570-2597610E-E4C6-4288-BEFB-97464B22C3B5Q44196403-C9CB5635-D598-4535-90A2-E41229B8D91BQ47606258-66DB47D2-B978-4960-B996-893011C24125
P2860
Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@ast
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@en
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@nl
type
label
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@ast
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@en
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@nl
prefLabel
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@ast
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@en
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Randomized trial of paclitaxel ...... palliation from chemotherapy.
@en
P2093
Anil Tulpule
Bruce J Dezube
David M Aboulafia
Jamie Von Roenn
Jeannette Y Lee
Joseph A Sparano
Mary Cianfrocca
Richard F Ambinder
Sandra Lee
Susan E Krown
P2860
P304
P356
10.1002/CNCR.25362
P407
P577
2010-08-01T00:00:00Z